包括CEO Kyle Gano在内的Neurocrine生物科学内部人员最近出售了大量股票。 Neurocrine Biosciences insiders, including CEO Kyle Gano, recently sold substantial stock portions.

神经系统生物科学公司(Neurocrine Biosciences)是一家研制神经系统和相关疾病药物的公司,最近看到几家内幕人员出售其库存的很大一部分。 Neurocrine Biosciences, a company that develops drugs for neurological and related disorders, saw several insiders sell significant portions of their stock recently. CEO Kyle Gano和其他内幕人士出售股票,减少了他们的所有权。 CEO Kyle Gano and other insiders sold shares, reducing their ownership. 该股票的市场上限为154.3亿美元,PE比率为40.86。 The stock has a market cap of $15.43 billion and a PE ratio of 40.86. 分析师前景喜忧参半,平均评为“机动购买”,价格指标为166.85美元。 Analysts have a mixed outlook, with an average "Moderate Buy" rating and a price target of $166.85.